Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid–induced adrenal suppression

Inhaled corticosteroids (ICSs) represent the mainstay of long-term treatment for asthma.1 With long-term use, even this cornerstone of asthma management has the potential for corticosteroid-induced adverse effects, such as decrease in linear growth and, more rarely, adrenal suppression.2,3 When patients experience these adverse effects, clinicians must seek and are confronted by alternative management approaches that may control asthma symptoms with little to no corticosteroid use. Allergen immunotherapy (AIT) is a viable treatment option for asthma in patients whose asthma is associated with allergic sensitization.

http://ift.tt/2ciKywZ